Articles from Flatiron Health

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced that its international oncology research network has tripled in size across the UK, Germany, and Japan over the past year—a milestone that marks an unprecedented acceleration in global cancer research collaboration and impact.

Flatiron Health today announced that the novel findings from its research, “Using large language models for scalable extraction of real-world progression events across multiple cancer types,” have been presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Artificial Intelligence and Machine Learning, which took place July 10-12, 2025, in Montreal, QC, Canada.

Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)."

Flatiron Health today announced its presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2025 Conference, set to take place May 13-16 in Montreal, QC, Canada. Flatiron’s real-world data is featured across 15+ pieces of research to be presented at the conference, including eight Flatiron authored research posters. Additionally, Flatiron will participate in a panel discussion on the role of real-world evidence in precision medicine, including how real-world data can be leveraged across international borders to inform regulatory and reimbursement decisions within diverse healthcare systems.

Flatiron Health, a healthtech company transforming clinical research through solutions that integrate research into everyday care, today announced they will partner with Veeva Systems, a global leader in cloud software for the life sciences industry. As part of the partnership, Flatiron Health will join the Veeva Product Partner Program.

Flatiron Health, a healthtech company transforming clinical research through technology that integrates research into everyday care, today announced a strategic partnership with Massive Bio, global leader in using artificial intelligence to streamline patient identification and recruitment for clinical trials, to expand patient identification capabilities and improve clinical trial enrollment across the U.S.

Flatiron Health, a healthtech company transforming clinical research through technology that integrates research into everyday care, today announced a collaboration with NRG Oncology (NRG), a clinical research consortium in the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN) comprised of over 1,300 worldwide research sites, to deploy Flatiron Clinical Pipe™ in a multicenter NRG clinical trial. Flatiron Clinical Pipe™, a cutting-edge electronic health record (EHR) to electronic data capture (EDC) connector, improves efficiency and reduces time and effort of clinical study data entry.

Flatiron Health, a healthtech company transforming clinical research through technology that integrates research into everyday care, today announced a collaboration to enable Flatiron Clinical Pipe™ at the University of Colorado Cancer Center (CU Cancer Center) and their clinical care partner UCHealth. Flatiron Clinical Pipe™, a cutting-edge electronic health record (EHR) to electronic data capture (EDC) connector, improves efficiency and reduces time and effort of clinical study data capture.

Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted abstracts for poster presentation.

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research, and Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced a strategic partnership aimed at accelerating clinical evidence generation for Exact Sciences’ molecular residual disease test (MRD), OncodetectTM. The partnership leverages Flatiron’s leading-edge clinical research platform to study a broad range of solid tumor types. The companies have already achieved first patient enrolled, marking a key milestone for the partnership.

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron Health-sponsored session, “How Holistic Real-World Evidence Generation Advances Breast Cancer Research.”

Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and participation in the speaking session, “A New Era in Research: Pragmatic Prospective Real-World Studies.”

Flatiron Health today announced their planned presence at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR Europe) 2024 Annual Meeting, including five accepted abstracts for poster presentation and participation in the workshop “From Data to Decisions: The Potential of RWE Transportability in Healthcare Decision Making.”

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced a milestone of over 1,000 research publications utilizing Flatiron’s electronic health record-derived RWD. This achievement reinforces Flatiron's position as a pioneer in the application of RWD and was made possible through its history of collaboration to support rigorous research projects across the oncology ecosystem, including the 20+ top global developers of oncology therapeutics, academic institutions, policy groups, and regulators around the world.

Flatiron Health, and Lifebit Biotech Ltd (UK, London; hereafter “Lifebit”), are expanding their collaboration into Japan to transform cancer care, facilitating ground breaking research by allowing for safe and secure access to real-world data (RWD).

Flatiron Health today announced its significant presence at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago this June. Nine abstracts led by Flatiron have been accepted for poster presentation and online publication. A comprehensive of all accepted research using Flatiron data is available via ASCO's website.

Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing the gap between care and research, today announced a collaboration with the Association of Cancer Care Centers (ACCC), a powerful network of more than 40,000 multidisciplinary practitioners from cancer care communities nationwide, to promote increased access to cancer clinical trials in the community setting and provide member practices with access to Flatiron Clinical Pipe™, a cutting-edge electronic health record (EHR) to electronic data capture (EDC) connector that improves efficiency and reduces time and effort of clinical study data capture.

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced the renewal of their collaboration with the National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education. The collaboration between Flatiron and the NCCN dates back to 2014, when Flatiron Health first launched a cloud-based repository of NCCN Member Institution data—the NCCN Quality & Outcomes Database.

Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing the gap between research and care, today announced a collaboration with the Medical University of South Carolina (MUSC), to bring Flatiron Assist™ to oncology care clinicians at MUSC Hollings Cancer Center.

Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC).

Flatiron Health is presenting multiple sessions at HMP Global’s Clinical Pathways Congress + Cancer Care Business Exchange, advancing the conversation among stakeholders who have interest, influence, and impact on the evolving business models and delivery of cancer care, with a focus on improving outcomes for patients.

Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA) to jointly develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced a partnership with the Leeds Teaching Hospitals NHS Trust (LTHT), one of largest acute hospital trusts in Europe. The entry into the United Kingdom marks a major milestone in Flatiron’s expansion as both a domestic and international market leader in oncology RWD.

Flatiron Health today announced that the company and its collaborators will present a total of 12 abstracts accepted for poster discussion, presentation, and online publication at this year’s American Society of Clinical Oncology (ASCO) Annual meeting, to be held in Chicago this June.

Building upon over a decade of experience providing high-quality, real-world oncology data, Flatiron Health has announced the expansion of their real-world evidence (RWE) offerings to include analytic, scientific, and consultative services, leveraging the high-quality foundational real-world data (RWD) assets that the company is well known for. Flatiron’s new Integrated RWE Solutions will include data and end-to-end services to provide a more flexible and fit-for-purpose approach to address growing oncology RWE needs—from early development through late stage commercialization.

Flatiron Health is pleased to announce their presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2023 Conference, held in Boston this May. A total of ten on-stage presentations and six research posters being presented at the conference highlight how innovations in oncology real-world data (RWD) continue to advance the discipline of real-world evidence (RWE) generation.

Flatiron Health announced a new collaboration today with Sanofi in their pursuit to redesign the clinical trial experience for sponsors, sites, and patients in the therapeutic area of oncology.

Flatiron Health is pleased to announce their attendance and presence at the ISPOR, The Professional Society for Health Economics and Outcomes Research Europe 2022 Conference, held in Vienna, Austria this year. A total of 7 presentations will be presented by Flatiron, including one oral podium presentation and one in-person poster being recognized as top 5% finalists for 2022 Research Presentation Awards. Research presented at this year’s ISPOR Europe represents an important milestone in Flatiron Health’s growth and leadership within real-world evidence and clinical research, as learnings from the experiences of every person with cancer in the US begin to inform and improve the lives of people living with cancer in many other parts of the world.

Flatiron HealthⓇ is pleased to announce today the appointment of two seasoned executives to the company’s executive leadership team: Bruce Gottlieb, as Chief Operating Officer (COO) and Ara Tucker, as Chief People Officer (CPO).

Flatiron HealthⓇ today announced the appointment of Javier Jimenez, MD, MPH, as Chief Medical Officer, effective June 1, 2022. In his new role, Dr. Jimenez will drive our vision for integrated evidence, harnessing new approaches to oncology evidence generation through Flatiron’s engaged care network and fit-for-purpose scientific methods and tools. His clinical expertise and proven leadership, as well as his extensive experience with real-world evidence, will continue to advance our scientific efforts and a future where we accelerate R&D and realize a more equitable and sustainable cancer care ecosystem. Dr. Jimenez succeeds Dr. Michael Vasconcelles, who will remain at Flatiron as a senior advisor through August 1, 2022.

Flatiron Health today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7.

Flatiron HealthⓇ today announced a partnership with Japan’s National Cancer Center Hospital East (NCCHE) to build a real-world database of patients with gastro-intestinal cancers.

Flatiron HealthⓇ today announced the appointment of Stephanie Reisinger as Senior Vice President and General Manager, Real-World Evidence (RWE), driving long-term strategy and growth for Flatiron’s RWE business unit.

Flatiron Health real-world data (RWD) supported the U.S. Food and Drug Administration (FDA)’s recent approval of a new dosing regimen for ERBITUX® (Eli Lilly and Company’s cetuximab) that can have a direct positive impact on the lives of patients with metastatic colorectal cancer (CRC) or squamous cell carcinoma of the head and neck (SCCHN).

Flatiron Health today announced eight abstracts have been accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8.